Lymphoma

The PRECIS study looked at consolidation treatment with autologous stem cell transplantation vs whole-brain radiation therapy in younger patients with CNS lymphoma.

Although many immunotherapies for AML have been explored, none have ever been shown to reduced relapse rates.

Researchers examined the effect of early progression in a real-world setting of follicular lymphoma patients.

The DYNAMO study investigated the oral PI3K gamma inhibitor duvelisib in heavily pretreated indolent non-Hodgkin lymphoma patients.

In this study, single-agent ofatumumab did not show superiority to rituximab or obinutuzumab, raising the question of whether ofatumumab should have a role in the treatment of follicular lymphoma.

The final results of the LNH-PRO-05 study showed that a combination of antiproliferative and immunomodulatory agents with chemo had good outcomes in follicular lymphoma patients.

The combination of ibrutinib and nivolumab showed promising clinical response in patients with Richter’s Transformation.

Is Aurora A kinase inhibitor alisertib superior to standard treatment protocol for peripheral T-cell lymphoma?

Dr. Copelan discusses the use of chimeric antigen receptor (CAR) T-cell therapy in non-Hodgkin lymphoma patients and how these therapies might improve upon the current standard of care.

Investigators evaluated whether AZD3463 can induce apoptosis in a dose-dependent manner in a subset of AML patients.

Researchers evaluated the primary mechanisms governing drug resistance and relapse in patients treated with crenolanib, an FLT3 inhibitor.

A retrospective study finds that younger mantle cell lymphoma patients may achieve longer PFS with AHCT consolidation.

Allogeneic transplantation was found not to improve overall outcome, in particular for patients who achieved MRD-negative status after induction.

A study investigates whether FL patients had fewer early disease progression events when assigned to treatment with obinutuzumab plus chemotherapy.

Is the continuation of maintenance rituximab beneficial post bendamustine plus rituximab treatment in FL Patients?

Guidelines for cancer screening in survivors of childhood HL may be refined based on the results of this extended follow-up study, say the researchers.

A new study published in Cancer compared ELN-2017 to ELN-2010 in terms of distinguishing prognosis in younger patients with newly diagosed AML.

Researchers reported on the impact of adding the Hedgehog pathway inhibitor glasdegib to low-dose cytarabine.

Researchers compared the ability of a novel prognostic score vs existing scores to identify patients with high-risk DLBCL.

In an interview with Cancer Network, Brad S. Kahl, MD, weighs in on the top CLL research presented at ASH 2018 in San Diego.

A study found follicular lymphoma patients staged with PET-CT and treated with radiotherapy appeared to have better outcomes than CT staging alone.

Despite improved outcomes seen in the rituximab era, the leading cause of death in patients with follicular lymphoma during the first decade remains lymphoma.

The US Food and Drug Administration recently approved a new agent for treatment of adult patients with relapsed or refractory acute myeloid leukemia.

The results of a follow-up analysis to the phase III MAVORIC study were presented at the ASH 2018 Annual Meeting & Exposition.

In the single-arm, multicenter, phase II part of the CAVALLI trial, the researchers analyzed the efficacy of 800-mg venetoclax plus R-CHOP in all first-line DLBCL patients.

Research presented at ASH 2018 examined whether checkpoint blockade therapy sensitizes patients with relapsed/refractory NHL to consequent treatment.

A new study has identified a clinically and biologically distinct subgroup of diffuse large B-cell lymphoma tumors.

A study looked at whether survivorship care plans were able to enhance patients' knowledge and adherence to physician recommendations.

Researchers studied clonal hematopoiesis of indeterminate potential (CHIP) as a way to assess risk for increased mortality in lymphoma patients.

Researchers developed an enhanced genomic model combining clinical factors and select gene mutations in order to better predict survival in patients with DLBCL who were administered first-line R-CHOP.